BlackRock, Inc. Reduces Stake in Edwards Lifesciences Corp

BlackRock, Inc. has filed a Schedule 13G/A amendment, disclosing a reduction in its ownership of Edwards Lifesciences Corp's common stock. As of September 30, 2025, BlackRock owns 44,267,376 shares, representing a 7.5% ownership stake. This marks a decrease of 11,379,856 shares (20.45%) from its previous holdings. The total value of the shares held is approximately $3.30 billion, reflecting a 24.08% decrease in value. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer. The filing was signed by Spencer Fleming, Managing Director, on October 17, 2025.